MARKET

ANIK

ANIK

Anika Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.70
+0.10
+0.46%
After Hours: 21.70 0 0.00% 16:00 05/26 EDT
OPEN
21.68
PREV CLOSE
21.60
HIGH
21.90
LOW
21.55
VOLUME
54.97K
TURNOVER
0
52 WEEK HIGH
48.37
52 WEEK LOW
19.95
MARKET CAP
315.60M
P/E (TTM)
-181.7420
1D
5D
1M
3M
1Y
5Y
New FDA 510(k) Clearance Expands Anika's Sports Medicine Soft Tissue Portfolio
Benzinga · 6d ago
Anika gets FDA clearance for X-Twist Knotless Fixation System
Anika Therapeutics (NASDAQ:ANIK), a developer focused on orthopedic care, announced on Friday that the U.S. Food and Drug Administration (FDA) granted it the 510(k) clearance for X-Twist Knotless Fixation System,
Seekingalpha · 6d ago
Anika Therapeutics Reports Received FDA 510(k) Clearance For X-Twist Knotless Fixation System
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration
Benzinga · 6d ago
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremitiesBEDFORD, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preserva...
GlobeNewswire · 6d ago
Sector Update: Health Care
MT Newswires · 6d ago
Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT Newswires · 6d ago
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 2, 2022, Anika granted non-statutory stock options (“Options”) cove...
GlobeNewswire · 05/13 21:00
Anika Therapeutics (NASDAQ:ANIK) shareholders have endured a 56% loss from investing in the stock five years ago
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...
Simply Wall St. · 05/10 14:50
More
No Data
Learn about the latest financial forecast of ANIK. Analyze the recent business situations of Anika Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
0.00%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ANIK stock price target is 37.50 with a high estimate of 46.00 and a low estimate of 29.00.
High46.00
Average37.50
Low29.00
Current 21.70
EPS
Actual
Estimate
-0.21-0.020.180.37
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 240
Institutional Holdings: 15.13M
% Owned: 104.00%
Shares Outstanding: 14.54M
TypeInstitutionsShares
Increased
41
659.31K
New
11
155.02K
Decreased
49
357.05K
Sold Out
14
118.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
President/Chief Executive Officer/Director
Cheryl Blanchard
Chief Financial Officer/Executive Vice President/Treasurer
Michael Levitz
Executive Vice President/General Counsel/Secretary
David Colleran
Executive Vice President/Director of Human Resources
Thomas Finnerty
Executive Vice President
James Loerop
Independent Director
Sheryl Conley
Independent Director
John Henneman
Independent Director
Raymond Land
Independent Director
Glenn Larsen
Independent Director
Stephen Richard
Independent Director
Jeffery Thompson
Independent Director
Susan Vogt
No Data
No Data
About ANIK
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. It is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. Its product categories include joint pain management therapies, joint preservation and restoration care, and Other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. Its joint preservation and restoration care products include HYALOFAST and TACTOSET. Its Other product family consists of Hyalobarrier and Hyaloglide.

Webull offers kinds of Anika Therapeutics Inc stock information, including NASDAQ:ANIK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIK stock methods without spending real money on the virtual paper trading platform.